In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the existence of gene mutations based on images of leukemia cells.

The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density neutrophil subsets in myelodysplastic syndromes (MDS), acute myeloid leukemia ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

The Zinnia has been called ‘The hardest working flower,’ known to withstand tough conditions, and bloom anyways.

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Acute myeloid leukemia (AML) is a highly aggressive and difficult-to-treat blood cancer. This study explores the role of ...

Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...

Bionano will host a webinar featuring the study’s lead author, Dr. Guilin Tang, who will discuss the study and its findings in ...

Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its ...